Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Controlled, Blinded, Parallel Group Study of the Safety and Efficacy of APC-0101 (SF-RI 1 Surfactant for Inhalation Combined With a Dedicated Delivery System) in Preterm Infants With Respiratory Distress Syndrome

NCT06776783 is registered in ClinicalTrials.gov with Aerogen Pharma Limited as lead sponsor.

NCT NCT06776783
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06776783 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Controlled, Blinded, Parallel Group Study of the Safety and Efficacy of APC-0101 (SF-RI 1 Surfactant for Inhalation Combined With a Dedicated Delivery System) in Preterm Infants With Respiratory Distress Syndrome
Lead sponsor
Aerogen Pharma Limited
Phase
Phase 3
Overall status
Recruiting
Start date
September 24, 2025
Completion date
May 31, 2029
Enrollment
520 (estimated)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

pre-term infants, respiratory distress syndrome